Explore Immunology

Meet your defenses.

A window into the immune system and the discoveries reshaping our understanding of it.

Start exploring.

Immunology

Nasal Vaccines May Offer Broad Defense Against Respiratory Germs

Most vaccines we receive are traditional shots in the arm, but scientists are looking closely at mucosal vaccines. These are treatments delivered directly to the mucous membranes, such as the lining of the nose or lungs. According to newly published research, administering a vaccine directly to the respiratory tract can put the local immune system on high alert before a germ even enters the body. What makes this approach particularly exciting is the type of defense it offers. Traditional vaccines rely on antigen-specific immunity, meaning they train the body to recognize and fight one specific virus or bacteria. However, researchers suggest that mucosal vaccines might provide broad-spectrum protection. By boosting the overall readiness of the respiratory system, these treatments could potentially help fend off a wider variety of invading pathogens. It is important to note that this research is still in its initial phases. The current findings are conceptual and lack the concrete quantitative data, sample sizes, and human clinical trial results needed to prove how well this works in practice. For now, it represents a promising preclinical idea rather than an immediate medical treatment.

Nature Immunology1 min read

Immunology

How an epigenetic memory of inflammation helps aging brain cells heal

Our brains rely on a specialized biological repair crew to maintain healthy nerve function. Nerve fibers are insulated by a protective coating called myelin. When this coating degrades, specialized cells known as oligodendrocyte progenitor cells (OPCs) step in to rebuild it in a process called remyelination. Scientists have long debated how passing periods of inflammation might impact the ability of these OPCs to repair damaged nerves over time. Recent research reveals that a temporary wave of inflammation throughout the body physically alters how DNA is packaged inside adult OPCs. This enduring change creates an epigenetic memory of the event, meaning the cell physically remembers the stress without changing its core genetic code. To study this, researchers exposed cells to two different inflammatory triggers, known as LPS and Poly(I:C). While both triggers caused long-lasting genetic modifications, only LPS taught the cells a specific, tolerance-like memory. Remarkably, this tolerance-like memory proved highly beneficial. When scientists looked at aged mice with damaged myelin, the mice that had experienced the LPS trigger had an easier time healing. Their OPCs were much better at maturing and stepping up to fix the damage, which ultimately protected the nerve fibers from further harm.

bioRxiv1 min read

Immunology

Researchers Find a New Way to Block Severe Allergic Reactions in Mice

When you experience an allergic reaction, cells in your immune system called mast cells are usually the culprits. These cells act like tiny biological alarms. When triggered by allergy antibodies known as IgE, mast cells release inflammatory chemicals in a process called degranulation, causing everything from itchy skin to severe anaphylaxis. For years, scientists have searched for better ways to stop this cellular alarm system from going off in the first place. Recently, researchers discovered that a specific internal cellular pathway, known as the IRE1-XBP1 axis, plays a crucial role in firing up these mast cells. To test if they could stop allergic reactions by blocking this pathway, the scientists used two specific chemical inhibitors called MBSA and KIRA6. When they treated mouse mast cells grown in the lab with these chemicals, the cells stopped releasing their inflammatory contents in response to allergy antibodies. Testing other cellular stress pathways did not yield the same results, showing that this specific biological axis is a unique trigger. To confirm their findings, the research team genetically reduced the levels of the XBP1 protein in the cells, which successfully lowered the allergic response. Furthermore, they tested the chemical inhibitors in live mice and found that the treatments significantly suppressed severe allergic reactions known as anaphylaxis. While these findings are promising, the researchers caution that the work is currently limited to early-stage laboratory and mouse models. Much more research is needed to establish whether this approach can be safely translated to human patients.

bioRxiv2 min read

Immunology

Experts weigh testing existing Ebola vaccine against new Congo outbreak

A severe Ebola outbreak is currently spreading through the Democratic Republic of the Congo. This health crisis is driven by a specific type of the virus known as the Bundibugyo species. Public health officials are facing immense hurdles in controlling the spread, largely because the outbreak is taking place in an active conflict zone where standard containment measures are exceptionally difficult to implement. Complicating matters further is the fact that there is no approved vaccine specifically designed to fight the Bundibugyo species. In response to this urgent need, scientists are considering an unconventional approach. They are evaluating Merck's Ervebo, a licensed vaccine created to target an entirely different type of the virus called the Zaire ebolavirus. Researchers are hoping that this existing shot might offer cross-protection, meaning a vaccine made for one virus type could still help the immune system defend against a closely related one. Public health experts stress that this strategy comes with major early-stage caveats. Deploying the Ervebo vaccine against this outbreak is considered a long shot. The scientific evidence suggesting it might actually protect people against the Bundibugyo strain is currently highly limited, but officials are weighing the option simply because the severe challenges on the ground demand creative solutions.

STAT News2 min read

Immunology

The Surprising Drivers of Childhood Vaccination Rates in Somalia

Childhood vaccines are one of the most reliable ways to keep kids healthy, but reaching every child remains a major challenge in many parts of the world. In a recent sweeping review of healthcare data in Somalia, researchers sought to understand exactly how many children are getting their shots and what factors influence those medical decisions. By pooling data from 11 different studies conducted between 2010 and 2025, the team found that overall vaccination rates remain alarmingly low. Only 42.2 percent of children are fully immunized, and a mere 16.1 percent have completed the full series of four basic vaccines. When the researchers looked into what makes a child more likely to be vaccinated, they found a mix of expected patterns and striking surprises. Unsurprisingly, mothers who had formal education and those who gave birth in medical facilities were significantly more likely to have their infants immunized. However, conventional wisdom was turned upside down when looking at geography. Children living in rural areas were actually 1.55 times more likely to get their shots than kids living in urban centers. The most unexpected discovery involved prenatal visits. Logically, mothers who see doctors frequently before giving birth should be more connected to the medical system. Yet, mothers who attended four or more pregnancy checkups were actually much less likely to ensure their children were immunized. The authors caution that because these findings rely on observational snapshot studies, they can highlight these unusual patterns but cannot definitively prove what is causing them.

PubMed2 min read

Immunology

How the immune system decides the outcome of a TB infection

When people think of tuberculosis, or TB, they often imagine a simple scenario where a person is either perfectly healthy or noticeably sick. However, scientists are increasingly viewing TB as an evolving clinical spectrum. At the center of this concept is a review article that explores how the body reacts to Mycobacterium tuberculosis, the bacteria responsible for the disease. The primary factor deciding where a patient lands on this spectrum is their own immune system. A person's immune response acts as the main determinant in whether an infection is successfully contained or whether it progresses into full-blown disease. If the immune defenses react effectively, the patient is protected. If not, the illness worsens. This biological tug-of-war is further complicated by the bacteria themselves. The natural diversity of different TB strains significantly alters how the germ and the human body interact. It is important to note that this publication is a broad discussion paper rather than a primary laboratory experiment. Instead of providing new clinical data or specific sample sizes, it synthesizes current knowledge to explain the intricate relationship between our immune defenses and varied bacterial strains.

Nature Immunology1 min read

Immunology

Training Our Immune Cells to Stop Allergic Reactions

Imagine your immune system has a master conductor directing how it responds to harmless things like pollen or peanuts. In our bodies, these conductors are called dendritic cells. According to a recent scientific review, these special cells play a dual role in allergic diseases. On one hand, they can trigger the type of inflammation that causes the sneezing, itching, and swelling we associate with allergies. On the other hand, they have the power to generate regulatory T cells, which act like peacemakers that calm the immune system down and prevent allergic reactions. When dendritic cells successfully teach the immune system to ignore harmless allergens, a process known as immune tolerance, they use a few complex tricks. The researchers note that these cells rely on multiple biological mechanisms to keep the peace. These include sending specific chemical messages called cytokines, changing how the cells use energy through metabolic reprogramming, and even altering how their genes are read, which scientists call epigenetic remodeling. The exciting part is that scientists are learning how to guide this system. By using microscopic delivery vehicles called nanoparticles or applying genetic engineering, researchers can reprogram dendritic cells. The goal is to force them into a stable, calming state that stops allergic reactions before they start. However, the researchers caution that this review focuses heavily on early laboratory studies, meaning these advanced treatments are still in the preclinical phase.

PubMed2 min read

Immunology

Unique Antibodies From 305 People Could Guide the Search for an HIV Vaccine

Creating a successful vaccine against HIV has been a lengthy challenge, largely because the virus constantly changes. Scientists believe the secret to finally building one lies in broadly neutralizing antibodies. These are special immune system proteins capable of recognizing and blocking many different strains of a virus. While most people do not produce these powerful defenders against HIV, a small number of individuals do so naturally. To better understand this rare immune response, researchers established a new project called the XbnAb cohort. They screened stored blood plasma from two large databases: the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study. Through this search, they identified 305 people living with HIV who naturally developed broadly neutralizing antibodies over the course of their infection. The main goal of gathering this biobank-based data is to figure out exactly how the human body builds these antibodies on its own. It is important to note that this is an early-stage, retrospective observational study. Researchers are not testing a new vaccine or therapeutic intervention right now. Instead, they are analyzing this historical data to see if it is feasible to trigger a similarly powerful immune response artificially through a future vaccine.

bioRxiv1 min read

Immunology

Shingles Vaccine Highly Effective for Autoimmune Patients

Patients with inflammatory rheumatic diseases, such as lupus, have immune systems that mistakenly attack their own bodies. Because they often take medications that suppress their immunity to manage these conditions, they are at a much higher risk of developing shingles. Shingles, or herpes zoster, is a painful skin rash caused by the reactivation of the chickenpox virus. Fortunately, researchers have found that a modern two-dose shot called the recombinant zoster vaccine is highly effective at preventing this condition. Real-world data shows the vaccine reduces the chance of a shingles relapse by about 95 percent in these vulnerable patients. A major concern for anyone with an autoimmune condition is whether a vaccine might accidentally trigger a "flare," causing their underlying disease symptoms to worsen. Reassuringly, controlled clinical trials indicate that the short-term risk of a flare after getting the shingles vaccine is generally no different than receiving a placebo. However, researchers are still paying close attention to real-world safety reports. A broad safety analysis of 920 autoimmune patients found that 8.5 percent experienced a disease flare after vaccination, representing a threefold increase in the odds of such events being reported. Patients with systemic lupus erythematosus appear to face a notably higher risk for these post-vaccination flares. Because of this, researchers emphasize that doctors should closely monitor these specific patients in the weeks following their shots. The crucial takeaway is that the risk of a temporary flare should prompt careful observation and patient counseling, rather than causing patients to avoid the vaccine entirely.

PubMed2 min read

Keep connecting the dots.

All topics ↗

Start exploring.

Keep connecting the dots.

Oncology ↗

Drug Development ↗

General Biotech ↗

A little science goes a long way.